QIAGEN and Myriad Genetics join forces for cancer companion diagnostics.

M2 EQUITYBITES-October 26, 2023-QIAGEN and Myriad Genetics join forces for cancer companion diagnostics

(C)2023 M2 COMMUNICATIONS http://www.m2.co.uk

Sample and assay technologies provider QIAGEN N.V. (NYSE:QGEN) (Frankfurt Prime Standard:QIA) and genetic testing and precision medicine company Myriad Genetics (NASDAQ:MYGN) announced on Thursday a strategic collaboration to advance companion diagnostic development in the field of cancer.

This partnership will focus on creating lab-developed and distributable kit-based companion diagnostic tests, leveraging QIAGEN's Sample to Insight solutions, including sample preparation, sequencing technologies and bioinformatics, along with Myriad Genetics' CLIA-certified lab platform and commercial infrastructure. Additionally, both...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT